Nucleotide synthesis pathway enzyme

“Nucleotide synthesis pathway enzymes” is not a single molecular target, but a functional category encompassing all enzymes involved in the biosynthesis (both de novo and salvage pathways) of purine and pyrimidine nucleotides, which are essential for DNA and RNA synthesis. These enzymes include (but are not limited to) phosphoribosyl pyrophosphate synthetase (PRPP synthetase), glutamine-PRPP amidotransferase (purine synthesis), carbamoyl phosphate synthetase, aspartate transcarbamoylase, dihydroorotase (pyrimidine synthesis), ribonucleotide reductase (converts ribonucleotides to deoxyribonucleotides), thymidylate synthase, and nucleoside and nucleotide kinases[1][2][4][5][8]. These enzymes are critical for cell survival and proliferation; their inhibitors are widely used as anticancer, immunosuppressive, or antimicrobial agents. However, grouping them as a single “target” is imprecise, as each enzyme may differ significantly in sequence, structure, function, regulation, and therapeutic implications[4][8]. Caveats / limitations: - The entry "Nucleotide synthesis pathway enzymes" is **not a single molecular entity**, but a broad group referring to multiple related enzymes. If your intention is to refer to a specific enzyme within the nucleotide synthesis pathways, such as ribonucleotide reductase, thymidylate synthase, or dihydrofolate reductase, a more precise canonical name should be specified[1][4][8]. Specific enzymes commonly considered individual therapeutic targets within this pathway include: - **Dihydrofolate reductase (DHFR)** - **Thymidylate synthase (TYMS)** - **Ribonucleotide reductase (RNR)** - **Inosine monophosphate dehydrogenase (IMPDH)** - **Carbamoyl phosphate synthetase II (CPSII)** - **Adenosine phosphoribosyltransferase (APRT)** - **Hypoxanthine-guanine phosphoribosyltransferase (HGPRT)** For structured data extraction, you should map entries to specific enzyme names supported by the context above, rather than the generic category.

Inhibition of enzyme activity in de novo or salvage pathway, leading to decrease in nucleotide pools and impaired nucleic acid synthesis; Disruption of DNA/RNA biosynthesis; Cell cycle arrest, especially in rapidly dividing cells